☰

Saswati Hazra, Ph.D. - Publications

Affiliations: 
2003 University of Southern California, Los Angeles, CA, United States 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy. Cancer Prevention Research (Philadelphia, Pa.). 7: 845-55. PMID 24913817 DOI: 10.1158/1940-6207.Capr-14-0063  0.331
2014 Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science Signaling. 7: ra29. PMID 24667376 DOI: 10.1126/Scisignal.2005125  0.363
2013 Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science Translational Medicine. 5: 196ra99. PMID 23903756 DOI: 10.1126/Scitranslmed.3005747  0.42
2013 Liclican EL, Hazra S, Larsen JE, Park SJ, Pagano PC, Walser TC, Krysan K, Minna JD, Dubinett SM. Abstract A08: The role of miR-125a in the pathogenesis of lung cancer Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-A08  0.336
2013 Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, et al. Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B106  0.412
2012 Hazra S, Lee J, Kim PS, Kim K, Liu L, Webster E, Fithian A, Singh S, Kang W. Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting. Journal of Clinical Oncology. 30: 10535-10535. DOI: 10.1200/Jco.2012.30.15_Suppl.10535  0.32
2012 Scaltriti M, Tao J, Juric D, Auricchio N, Castel P, Morse N, Kim P, Singh S, Hazra S, Hembrough T, Burrows J, Baselga J. Abstract 4471: Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer. Cancer Research. 73: 4471-4471. DOI: 10.1158/1538-7445.Am2013-4471  0.409
2012 Lee G, Gardner BK, Hazra S, Kachroo P, Lee M, Krysan K, Walser TC, Larsen JE, Girard L, Wistuba II, Minna JD, Dubinett SM. Abstract 2558: VEGF-dependent suppression of prostaglandin transporter (PGT) expression in Kras mutant human bronchial epithelial cells Cancer Research. 72: 2558-2558. DOI: 10.1158/1538-7445.Am2012-2558  0.321
2012 Hazra S, Liu L, Webster E, Fithian A, Lee T, Magonova K, Barham R, Kim P, Singh S. Abstract 1217: Detection of HER2 expression and phosphorylation in breast cancer CTC samples by CEER™ Cancer Research. 72: 1217-1217. DOI: 10.1158/1538-7445.Am2012-1217  0.377
2012 Tao J, Ip P, Auricchio N, Juric D, Yu M, Shyamala M, Kim P, Singh S, Hazra S, Haber D, Scaltriti M, Baselga J. Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S5-7  0.35
2011 Kachroo P, Zhang L, Walser TC, Cui X, Hazra S, Lin QY, Minna JD, Dubinett SM, Lee JM. Abstract 4268: Interleukin-27 inhibits angiogenesis in non-small cell lung cancer Cancer Research. 71: 4268-4268. DOI: 10.1158/1538-7445.Am2011-4268  0.375
2011 Lee JM, Zhang L, Kachroo P, Cui X, Hazra S, Walser TC, Minna JD, Sharma S, Dubinett SM. Abstract 3425: Interleukin-27 inhibits epithelial mesenchymal transition in lung carcinogenesis Cancer Research. 71: 3425-3425. DOI: 10.1158/1538-7445.Am2011-3425  0.384
2010 Hazra S, Lee G, Grant J, Walser T, Prasad S, Larsen JE, Minna J, Dubinett SM. Abstract B57: Modulation of prostaglandin E2 by statins in human bronchial epithelial cells harboring K-ras mutation: The potential advantage of combination therapy Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-B57  0.376
2010 Hazra S, Gardner BK, Krysan K, Walser TC, Larsen JE, Pertsemlidis A, Shay JW, Minna JD, Spira A, Dubinett SM. Abstract A31: The role of microRNA 125a‐3P in the pathogenesis of lung cancer Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A31  0.413
2010 Grant JL, Walser TC, Yanagawa J, Lee G, Minna JD, Prasad S, Hazra S, Dubinett SM. Abstract 5592: Lovastatin and low dose celecoxib decrease proliferation and inflammation in a cellular model of lung pre-malignancy Cancer Research. 70: 5592-5592. DOI: 10.1158/1538-7445.Am10-5592  0.422
2008 Dubinett SM, Mao JT, Hazra S. Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase. Cancer Prevention Research (Philadelphia, Pa.). 1: 223-5. PMID 19138963 DOI: 10.1158/1940-6207.Capr-08-0148  0.342
2008 Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. Ppar Research. 2008: 790568. PMID 18769553 DOI: 10.1155/2008/790568  0.439
2008 Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. Journal of Translational Medicine. 6: 38. PMID 18644162 DOI: 10.1186/1479-5876-6-38  0.357
2008 Tsukamoto H, She H, Hazra S, Cheng J, Wang J. Fat paradox of steatohepatitis. Journal of Gastroenterology and Hepatology. 23: S104-7. PMID 18336651 DOI: 10.1111/J.1440-1746.2007.05294.X  0.574
2008 Hazra S, Krysan K, Walser T, Gardner B, Lee G, Shay J, Minna J, Horvath S, Dubinett S. Abstract A136: A systems approach to the preclinical evaluation of targeted chemoprevention for lung cancer Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-A136  0.379
2007 Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Review of Anticancer Therapy. 7: 1405-21. PMID 17944566 DOI: 10.1586/14737140.7.10.1405  0.422
2007 Hazra S, Dubinett SM. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 77: 51-8. PMID 17697767 DOI: 10.1016/J.Plefa.2007.05.006  0.449
2007 Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Molecular Pharmacology. 71: 1715-20. PMID 17412838 DOI: 10.1124/Mol.106.033357  0.453
2007 Cui X, Zhang L, Luo J, Rajasekaran A, Hazra S, Cacalano N, Dubinett SM. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene. 26: 4253-60. PMID 17237818 DOI: 10.1038/Sj.Onc.1210222  0.47
2006 Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. Journal of Gastroenterology and Hepatology. 21: S102-5. PMID 16958658 DOI: 10.1111/J.1440-1746.2006.04573.X  0.609
2005 Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clinical Lung Cancer. 7: 30-9. PMID 16098242 DOI: 10.3816/Clc.2005.N.019  0.392
2005 She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. The Journal of Biological Chemistry. 280: 4959-67. PMID 15537655 DOI: 10.1074/Jbc.M410078200  0.615
2004 Hazra S, Miyahara T, Rippe RA, Tsukamoto H. PPAR Gamma and Hepatic Stellate Cells. Comparative Hepatology. 3: S7. PMID 14960159 DOI: 10.1186/1476-5926-2-S1-S7  0.585
2004 Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. The Journal of Biological Chemistry. 279: 11392-401. PMID 14702344 DOI: 10.1074/Jbc.M310284200  0.591
2003 SHE H, HAZRA S, XIONG S, WANG J, SUNG C, TSUKAMOTO H. 211 Adipogenic regulation of hepatic stellate cell transdifferentiation Hepatology. 38: 258-258. DOI: 10.1016/S0270-9139(03)80254-9  0.552
Show low-probability matches.